aspirin has been researched along with Metabolic Syndrome in 50 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The EAGeR trial randomly assigned 1228 women with a history of pregnancy loss to receive 81 mg aspirin or placebo for up to six menstrual cycles of attempting pregnancy and, if they became pregnant, throughout pregnancy." | 9.30 | Metabolic Syndrome and the Effectiveness of Low-dose Aspirin on Reproductive Outcomes. ( Hill, M; Kim, K; Mendola, P; Mumford, SL; Naimi, AI; Nobles, CJ; Perkins, NJ; Schisterman, EF; Silver, RM; Sjaarda, L, 2019) |
| "The pharmacologic effect of aspirin is suboptimal in 15% of patients with SLE but in none of the control subjects, and the suboptimal response was associated with metabolic syndrome, obesity, and higher CRP concentrations." | 9.19 | Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. ( Avalos, I; Chung, CP; Kawai, VK; Milne, GL; Oates, JA; Oeser, A; Solus, JF; Stein, CM, 2014) |
| "A prospective, clinical trial of 35 patients with mixed dyslipidemia who were treated with niacin-ER and SV." | 9.14 | Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010) |
| "One hundred and twenty-one consecutive patients with metabolic syndrome were randomized into three groups, receiving 100 mg/day of aspirin, 300 mg/day of aspirin or a placebo, respectively, for 2 weeks." | 9.14 | Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. ( Adhikari, CM; Gao, XR; Guo, XG; He, XY; Lin, J; Peng, LY; Zhai, YS; Zhang, LY; Zuo, ZY, 2009) |
| " Aspirin is known as a potent anti-inflammatory drug, but its role in adipogenesis, adipocyte-specific inflammation, and metabolic syndrome is not well characterized." | 8.12 | Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice. ( Ahmed, F; Amin, MT; Begum, R; Bhowmik, DR; Hossain, MS; Islam, MA; Roy, S, 2022) |
| "The adjunctive use of ω-3 and low-dose aspirin to periodontal debridement might have potential benefits in the treatment of periodontitis in a patient with metabolic syndrome." | 7.96 | Omega-3 Fatty Acids and Low-Dose Aspirin in the Treatment of Periodontitis and Metabolic Syndrome: Case Report. ( Andere, NMRB; Araujo, CF; Dos Santos, NC; Miguel, MMV; Santamaria, MP; Van Dyke, T; Westphal, MRA, 2020) |
| "Aspirin is recommended for primary prevention in patients with metabolic syndrome (MetS)." | 7.75 | The prevalence of aspirin resistance in patients with metabolic syndrome. ( Aras, D; Cağirci, G; Cay, S; Geyik, B; Ozdemir, O; Oztürk, S; Topaloğlu, S, 2009) |
| " The aim of the present study was to examine the effect of chronic administration of aspirin on metabolic and cardiovascular parameters in fructose-fed rats (FFR), an experimental model of metabolic syndrome." | 7.75 | Effect of chronic aspirin administration on an experimental model of metabolic syndrome. ( González, ES; Lama, MC; Miatello, RM; Renna, NF; Vazquez, MA, 2009) |
| "Among persons with an increased risk for CAD, metabolic syndrome was independently associated with overall greater platelet aggregation and activation at baseline and lesser, though significant, effect following aspirin, suggesting that low-dose aspirin therapy alone may not be sufficient to provide optimal antiplatelet protection in persons with metabolic syndrome." | 7.75 | Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. ( Becker, DM; Becker, LC; Faraday, N; Moy, TF; Vaidya, D; Yanek, LR, 2009) |
| "We concluded that the frequency of aspirin resistance confirmed in this cohort of patients with metabolic syndrome was higher in patients with a lower diastolic blood pressure, higher hs-CRP levels and atherosclerotic changes in their carotid arteries." | 7.74 | The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. ( Agacdiken, A; Baytugan, NZ; Kahraman, G; Kilic, T; Komsuoglu, B; Sahin, T; Ural, D; Ural, E, 2007) |
| "Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrombotic events." | 6.74 | PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. ( Cable, G; Willerson, JT; Yeh, ET, 2009) |
| "Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States." | 6.45 | Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. ( Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR, 2009) |
| "The EAGeR trial randomly assigned 1228 women with a history of pregnancy loss to receive 81 mg aspirin or placebo for up to six menstrual cycles of attempting pregnancy and, if they became pregnant, throughout pregnancy." | 5.30 | Metabolic Syndrome and the Effectiveness of Low-dose Aspirin on Reproductive Outcomes. ( Hill, M; Kim, K; Mendola, P; Mumford, SL; Naimi, AI; Nobles, CJ; Perkins, NJ; Schisterman, EF; Silver, RM; Sjaarda, L, 2019) |
| "The pharmacologic effect of aspirin is suboptimal in 15% of patients with SLE but in none of the control subjects, and the suboptimal response was associated with metabolic syndrome, obesity, and higher CRP concentrations." | 5.19 | Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. ( Avalos, I; Chung, CP; Kawai, VK; Milne, GL; Oates, JA; Oeser, A; Solus, JF; Stein, CM, 2014) |
| "One hundred and twenty-one consecutive patients with metabolic syndrome were randomized into three groups, receiving 100 mg/day of aspirin, 300 mg/day of aspirin or a placebo, respectively, for 2 weeks." | 5.14 | Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. ( Adhikari, CM; Gao, XR; Guo, XG; He, XY; Lin, J; Peng, LY; Zhai, YS; Zhang, LY; Zuo, ZY, 2009) |
| "A prospective, clinical trial of 35 patients with mixed dyslipidemia who were treated with niacin-ER and SV." | 5.14 | Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010) |
| "Clinical trials investigating the role of aspirin in primary prevention have led to an adjustment in the indication for aspirin in metabolic syndrome patients at intermediate risk of a cardiovascular event." | 4.86 | A practical approach to the metabolic syndrome: review of current concepts and management. ( Blaha, MJ; Blumenthal, RS; Defilippis, AP; Tota-Maharaj, R, 2010) |
| " We used the search terms metabolic syndrome, abdominal obesity, waist circumference, insulin resistance, cardiovascular disease, prediabetes, diabetes, treatment, prevention, aspirin, hypertension, cholesterol, atherogenic dyslipidemia, lifestyle therapy, diet, and exercise." | 4.84 | A practical "ABCDE" approach to the metabolic syndrome. ( Bansal, S; Blaha, MJ; Blumenthal, RS; Defilippis, AP; Golden, SH; Rouf, R, 2008) |
| " Aspirin is known as a potent anti-inflammatory drug, but its role in adipogenesis, adipocyte-specific inflammation, and metabolic syndrome is not well characterized." | 4.12 | Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice. ( Ahmed, F; Amin, MT; Begum, R; Bhowmik, DR; Hossain, MS; Islam, MA; Roy, S, 2022) |
| "The adjunctive use of ω-3 and low-dose aspirin to periodontal debridement might have potential benefits in the treatment of periodontitis in a patient with metabolic syndrome." | 3.96 | Omega-3 Fatty Acids and Low-Dose Aspirin in the Treatment of Periodontitis and Metabolic Syndrome: Case Report. ( Andere, NMRB; Araujo, CF; Dos Santos, NC; Miguel, MMV; Santamaria, MP; Van Dyke, T; Westphal, MRA, 2020) |
| " This adherence was concerned particularly with co-medication in patients diagnosed with hypertension, aspirin prescription in elderly patients and the achievement of target lipid levels following the prescription of statins." | 3.79 | Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. ( Hintersteiner, J; Johnson, J; Kamyar, MR; Kautzky, A; Kautzky-Willer, A; Lemmens-Gruber, R; Saukel, J; Stich, K, 2013) |
| "We investigated the effects of the hydrogen sulfide (H₂S)-releasing derivatives of aspirin (ACS14) and salicylic acid (ACS21) in a rat model of metabolic syndrome induced by glutathione (GSH) depletion, causing hypertension and other pathological cardiovascular alterations." | 3.76 | Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats. ( Berti, F; Del Soldato, P; Manfredi, B; Rossoni, G; Sparatore, A; Tazzari, V; Trivulzio, S, 2010) |
| "Among persons with an increased risk for CAD, metabolic syndrome was independently associated with overall greater platelet aggregation and activation at baseline and lesser, though significant, effect following aspirin, suggesting that low-dose aspirin therapy alone may not be sufficient to provide optimal antiplatelet protection in persons with metabolic syndrome." | 3.75 | Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. ( Becker, DM; Becker, LC; Faraday, N; Moy, TF; Vaidya, D; Yanek, LR, 2009) |
| " The aim of the present study was to examine the effect of chronic administration of aspirin on metabolic and cardiovascular parameters in fructose-fed rats (FFR), an experimental model of metabolic syndrome." | 3.75 | Effect of chronic aspirin administration on an experimental model of metabolic syndrome. ( González, ES; Lama, MC; Miatello, RM; Renna, NF; Vazquez, MA, 2009) |
| "Aspirin is recommended for primary prevention in patients with metabolic syndrome (MetS)." | 3.75 | The prevalence of aspirin resistance in patients with metabolic syndrome. ( Aras, D; Cağirci, G; Cay, S; Geyik, B; Ozdemir, O; Oztürk, S; Topaloğlu, S, 2009) |
| "We concluded that the frequency of aspirin resistance confirmed in this cohort of patients with metabolic syndrome was higher in patients with a lower diastolic blood pressure, higher hs-CRP levels and atherosclerotic changes in their carotid arteries." | 3.74 | The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. ( Agacdiken, A; Baytugan, NZ; Kahraman, G; Kilic, T; Komsuoglu, B; Sahin, T; Ural, D; Ural, E, 2007) |
| "Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrombotic events." | 2.74 | PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. ( Cable, G; Willerson, JT; Yeh, ET, 2009) |
| "Pregnancy is a specific state of heightened coagulability related to the increase in procoagulant agents and to the reduced fibrinolysis." | 2.50 | Anticoagulant therapy in pregnant patients with metabolic syndrome: a review. ( Kimber-Trojnar, Z; Leszczynska-Gorzelak, B; Mierzynski, R; Oleszczuk, J; Poniedzialek-Czajkowska, E, 2014) |
| "Obesity is associated with increased cardiovascular disease." | 2.48 | Platelet activation in obesity and metabolic syndrome. ( Davì, G; Guagnano, MT; Liani, R; Santilli, F; Vazzana, N, 2012) |
| "Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States." | 2.45 | Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. ( Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR, 2009) |
| "The Metabolic syndrome is a widely prevalent and multi-factorial disorder." | 2.43 | Metabolic syndrome. ( Agarwal, PK; Gogia, A, 2006) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| ": The prevalence of hypertension, type 2 diabetes mellitus (DM2) and the metabolic syndrome continues to increase in Latin America, while the rates of diagnosis, treatment and control of these disorders remain low." | 1.51 | Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. ( Accini, JL; Alcocer, L; Barbosa, E; Camacho, PA; Cobos, L; Coca, A; Diaz, M; Lanas, F; López-Jaramillo, P; Molina, DI; Pasquel, M; Ponte-Negretti, CI; Sanchez, R; Sebba-Barroso, W; Wyss, F; Zanchetti, A, 2019) |
| "A possible association between prostate cancer and metabolic syndrome has recently been observed." | 1.43 | [Common medications and prostate cancer : what is the association ?] ( Berthold, D; Grilo, N; Jichlinski, P; M'Baya, O; Rakauskas, A; Valerio, M, 2016) |
| "Women with CHD also had a higher rate of cerebral ischemia than did men (27." | 1.36 | Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. ( Gerhat, D; Handisurya, A; Hudson, S; Kamyar, MR; Kautzky-Willer, A; Lemmens-Gruber, R; Luger, A; Stemer, G, 2010) |
| "The metabolic syndrome is present in about half of individuals with symptomatic intracranial atherosclerotic disease and is associated with a substantially higher risk of major vascular events." | 1.33 | Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. ( Chimowitz, M; Lynn, MJ; Ovbiagele, B; Saver, JL, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (54.00) | 29.6817 |
| 2010's | 19 (38.00) | 24.3611 |
| 2020's | 4 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roy, S | 1 |
| Bhowmik, DR | 1 |
| Begum, R | 1 |
| Amin, MT | 1 |
| Islam, MA | 1 |
| Ahmed, F | 1 |
| Hossain, MS | 1 |
| Dos Santos, NC | 1 |
| Araujo, CF | 1 |
| Andere, NMRB | 1 |
| Miguel, MMV | 1 |
| Westphal, MRA | 1 |
| Van Dyke, T | 1 |
| Santamaria, MP | 1 |
| Korkushko, OV | 1 |
| Gorban, EM | 1 |
| Bondarenko, OV | 1 |
| Antonyuk-Shcheglova, IA | 1 |
| Naskalova, SS | 1 |
| Parshykov, OV | 1 |
| Utko, NO | 1 |
| Gavalko, AV | 1 |
| Shatilo, VB | 1 |
| Duzhak, GV | 1 |
| Wiśniewski, A | 1 |
| Rakauskas, A | 1 |
| Grilo, N | 1 |
| M'Baya, O | 1 |
| Jichlinski, P | 1 |
| Valerio, M | 1 |
| Berthold, D | 1 |
| López-Jaramillo, P | 1 |
| Barbosa, E | 1 |
| Molina, DI | 1 |
| Sanchez, R | 1 |
| Diaz, M | 1 |
| Camacho, PA | 1 |
| Lanas, F | 1 |
| Pasquel, M | 1 |
| Accini, JL | 1 |
| Ponte-Negretti, CI | 1 |
| Alcocer, L | 1 |
| Cobos, L | 1 |
| Wyss, F | 1 |
| Sebba-Barroso, W | 1 |
| Coca, A | 1 |
| Zanchetti, A | 1 |
| Nobles, CJ | 1 |
| Mendola, P | 1 |
| Mumford, SL | 1 |
| Kim, K | 1 |
| Sjaarda, L | 1 |
| Hill, M | 1 |
| Silver, RM | 1 |
| Naimi, AI | 1 |
| Perkins, NJ | 1 |
| Schisterman, EF | 1 |
| Stevenson, JC | 1 |
| Zomer, E | 1 |
| Owen, A | 1 |
| Magliano, DJ | 1 |
| Ademi, Z | 1 |
| Reid, CM | 1 |
| Liew, D | 1 |
| Kautzky-Willer, A | 2 |
| Stich, K | 1 |
| Hintersteiner, J | 1 |
| Kautzky, A | 1 |
| Kamyar, MR | 2 |
| Saukel, J | 1 |
| Johnson, J | 1 |
| Lemmens-Gruber, R | 2 |
| Kawai, VK | 1 |
| Avalos, I | 1 |
| Oeser, A | 1 |
| Oates, JA | 2 |
| Milne, GL | 1 |
| Solus, JF | 1 |
| Chung, CP | 1 |
| Stein, CM | 1 |
| Mierzynski, R | 1 |
| Poniedzialek-Czajkowska, E | 1 |
| Kimber-Trojnar, Z | 1 |
| Leszczynska-Gorzelak, B | 1 |
| Oleszczuk, J | 1 |
| Mao, Y | 1 |
| Lei, L | 1 |
| Su, J | 1 |
| Yu, Y | 1 |
| Liu, Z | 1 |
| Huo, Y | 1 |
| Barden, AE | 1 |
| Mas, E | 1 |
| Croft, KD | 1 |
| Phillips, M | 1 |
| Mori, TA | 1 |
| Katare, PB | 1 |
| Banerjee, SK | 1 |
| Schrier, RW | 1 |
| Bogaert, YE | 1 |
| Blaha, MJ | 2 |
| Bansal, S | 1 |
| Rouf, R | 1 |
| Golden, SH | 1 |
| Blumenthal, RS | 2 |
| Defilippis, AP | 2 |
| Renna, NF | 1 |
| Vazquez, MA | 1 |
| Lama, MC | 1 |
| González, ES | 1 |
| Miatello, RM | 1 |
| Engberding, N | 1 |
| Wenger, NK | 1 |
| Anfossi, G | 1 |
| Russo, I | 1 |
| Trovati, M | 1 |
| Vaduganathan, M | 1 |
| Alviar, CL | 1 |
| Arikan, ME | 1 |
| Tellez, A | 1 |
| Guthikonda, S | 1 |
| DeLao, T | 1 |
| Granada, JF | 1 |
| Kleiman, NS | 1 |
| Ballantyne, CM | 1 |
| Lev, EI | 1 |
| Schlossberg, D | 1 |
| Vaidya, D | 1 |
| Yanek, LR | 1 |
| Faraday, N | 1 |
| Moy, TF | 1 |
| Becker, LC | 1 |
| Becker, DM | 1 |
| Gardner, M | 1 |
| Palmer, J | 1 |
| Manrique, C | 1 |
| Lastra, G | 1 |
| Gardner, DW | 1 |
| Sowers, JR | 1 |
| Gao, XR | 1 |
| Adhikari, CM | 1 |
| Peng, LY | 1 |
| Guo, XG | 1 |
| Zhai, YS | 1 |
| He, XY | 1 |
| Zhang, LY | 1 |
| Lin, J | 1 |
| Zuo, ZY | 1 |
| Kappagoda, CT | 1 |
| Amsterdam, EA | 1 |
| Willerson, JT | 1 |
| Cable, G | 1 |
| Yeh, ET | 1 |
| Cağirci, G | 1 |
| Ozdemir, O | 1 |
| Geyik, B | 1 |
| Cay, S | 1 |
| Oztürk, S | 1 |
| Aras, D | 1 |
| Topaloğlu, S | 1 |
| Tota-Maharaj, R | 1 |
| Rossoni, G | 1 |
| Manfredi, B | 1 |
| Tazzari, V | 1 |
| Sparatore, A | 1 |
| Trivulzio, S | 1 |
| Del Soldato, P | 1 |
| Berti, F | 1 |
| Salgado, BJ | 1 |
| Salgado, JV | 1 |
| Dos Santos, AM | 1 |
| Casulari, LA | 1 |
| Gerhat, D | 1 |
| Handisurya, A | 1 |
| Stemer, G | 1 |
| Hudson, S | 1 |
| Luger, A | 1 |
| Yoshikawa, Y | 1 |
| Adachi, Y | 1 |
| Yasui, H | 1 |
| Hattori, M | 1 |
| Sakurai, H | 1 |
| Santilli, F | 1 |
| Vazzana, N | 1 |
| Liani, R | 1 |
| Guagnano, MT | 1 |
| Davì, G | 1 |
| Smith, JP | 1 |
| Haddad, EV | 1 |
| Taylor, MB | 1 |
| Oram, D | 1 |
| Blakemore, D | 1 |
| Chen, Q | 1 |
| Boutaud, O | 1 |
| Perera, M | 1 |
| Suarez, A | 1 |
| Luzardo, H | 1 |
| Lopez, J | 1 |
| Molero, T | 1 |
| Ali Raza, J | 1 |
| Movahed, A | 1 |
| Tracy, RP | 1 |
| Ridker, PM | 1 |
| Shields, TM | 1 |
| Hennekens, CH | 1 |
| Löbner, K | 1 |
| Füchtenbusch, M | 1 |
| Moser, M | 1 |
| Falkner, B | 1 |
| Weber, MA | 1 |
| Keilson, LM | 1 |
| Gogia, A | 1 |
| Agarwal, PK | 1 |
| Ovbiagele, B | 1 |
| Saver, JL | 1 |
| Lynn, MJ | 1 |
| Chimowitz, M | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Karagiannis, A | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Kraiem, S | 1 |
| Abassi, C | 1 |
| Annabi, N | 1 |
| Smaali, I | 1 |
| Issaa, I | 1 |
| Wali, M | 1 |
| Malou, M | 1 |
| Hannachi, S | 1 |
| Longo, S | 1 |
| Battikh, K | 1 |
| Slimane, ML | 1 |
| Kahraman, G | 1 |
| Sahin, T | 1 |
| Kilic, T | 1 |
| Baytugan, NZ | 1 |
| Agacdiken, A | 1 |
| Ural, E | 1 |
| Ural, D | 1 |
| Komsuoglu, B | 1 |
| Berry, C | 1 |
| Tardif, JC | 1 |
| Bourassa, MG | 1 |
| Franco, OH | 1 |
| Karnik, K | 1 |
| Bonneux, L | 1 |
| Hellwig, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Omega-3 Polyunsaturated Fatty Acids Daily Supplementation Plus Low-dose Aspirin as Adjunct to Full-mouth Periodontal Ultrasonic Debridement for the Treatment of Chronic Periodontitis in Type 2 Diabetics: Randomized Clinical Trial[NCT02800252] | 75 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | |||
| Vascular Damage in Systemic Lupus Erythematosus (SLE)[NCT00731302] | Phase 1 | 70 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease[NCT00753935] | Early Phase 1 | 92 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263] | 133 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Thromboxane A2, the major product of cyclooxygenase cytochrome oxidase (COX-1) in platelets, induces platelet aggregation. Thromboxane B2 is an inactive metabolite/product of thromboxane A2. This primary outcome measures the extent of inhibition of platelet COX-1 by measuring the amount of the metabolite thromboxane B2 in serum. (NCT00753935)
Timeframe: after 2 weeks on aspirin
| Intervention | ng/mL (Median) |
|---|---|
| Enteric-coated Aspirin | 5.02 |
| Chewable Aspirin | 2.78 |
18 reviews available for aspirin and Metabolic Syndrome
| Article | Year |
|---|---|
Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention.
Topics: Aspirin; Biological Availability; Clopidogrel; Drug Interactions; Drug Resistance; Humans; Ischemic | 2021 |
Anticoagulant therapy in pregnant patients with metabolic syndrome: a review.
Topics: Animals; Anticoagulants; Aspirin; Female; Fondaparinux; Heparin; Humans; Metabolic Syndrome; Polysac | 2014 |
Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Topics: Allopurinol; Aspirin; Bromocriptine; Cardiovascular Diseases; Clonidine; Colesevelam Hydrochloride; | 2016 |
A practical "ABCDE" approach to the metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diet Therapy; Early Diagnosis; Evidence-Based M | 2008 |
Cardiovascular disease prevention tailored for women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Choleste | 2008 |
Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Humans; Metabolic Syndrome; Pl | 2008 |
Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
Topics: Aspirin; Blood Coagulation; Blood Glucose; Blood Platelets; Cardiovascular Agents; Cardiovascular Di | 2009 |
A practical approach to the metabolic syndrome: review of current concepts and management.
Topics: Aspirin; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndro | 2010 |
Platelet activation in obesity and metabolic syndrome.
Topics: Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Metabolic Syndrome; Obesity | 2012 |
Current concepts of cardiovascular diseases in diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus | 2003 |
Inflammation, the metabolic syndrome and cardiovascular risk.
Topics: Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitu | 2003 |
Management of metabolic syndrome: aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Metabolic Syndrome; Stroke | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arte | 2004 |
Metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Humans; Hydroxymethylglutaryl | 2006 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
[Screening and management of coronary artery disease in diabetic patients].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2006 |
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Disease; Diabetes | 2007 |
The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Drug Incompatibility; | 2007 |
8 trials available for aspirin and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic Syndrome and the Effectiveness of Low-dose Aspirin on Reproductive Outcomes.
Topics: Abortion, Spontaneous; Adult; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug A | 2019 |
Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; C-Reactive Protein; Chi-Square Distribution; Cyclooxyge | 2014 |
Regulators of G protein signaling are up-regulated in aspirin-resistant platelets from patients with metabolic syndrome.
Topics: Aged; Aspirin; Blood Platelets; Cohort Studies; Cross-Sectional Studies; Female; GTP-Binding Protein | 2014 |
Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Combined Modality Therapy; Cyclooxyge | 2015 |
Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Disea | 2009 |
PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Biomarkers; C-Re | 2009 |
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidem | 2010 |
Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors | 2012 |
24 other studies available for aspirin and Metabolic Syndrome
| Article | Year |
|---|---|
Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Aspirin; Blood Glucose; Body Weight; Diet, High-F | 2022 |
Omega-3 Fatty Acids and Low-Dose Aspirin in the Treatment of Periodontitis and Metabolic Syndrome: Case Report.
Topics: Aspirin; Chronic Periodontitis; Fatty Acids, Omega-3; Gingival Crevicular Fluid; Humans; Metabolic S | 2020 |
APPLICATION OF QUERCETIN FOR CORRECTION OF THE IMPAIRMENT OF THE FUNCTIONAL STATE OF THE ENDOTHELIUS OF VESSELS (CLINICAL AND EXPERIMENTAL STUDY).
Topics: Acetylcysteine; Adipose Tissue; Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thor | 2020 |
[Common medications and prostate cancer : what is the association ?]
Topics: Aspirin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metaboli | 2016 |
Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2019 |
BMS consensus statement for primary prevention of coronary heart disease in women.
Topics: Age Factors; Antihypertensive Agents; Aspirin; Coronary Disease; Diet; Estrogen Replacement Therapy; | 2019 |
Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug | 2013 |
Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Complicat | 2013 |
Stemming the obesity-diabetes epidemic: lifestyle changes and therapeutics.
Topics: Aspirin; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hy | 2008 |
Effect of chronic aspirin administration on an experimental model of metabolic syndrome.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Aspirin; Blood Glucose; Blood Pressure; Bod | 2009 |
Platelet reactivity and response to aspirin in subjects with the metabolic syndrome.
Topics: Adult; Aspirin; Blood Platelets; Female; Humans; Male; Metabolic Syndrome; Platelet Aggregation Inhi | 2008 |
[Does JUPITER change the daily routine of our practice?].
Topics: Adult; Age Factors; Aged; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Female; Humans; Hydr | 2009 |
Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components.
Topics: Adult; Arachidonic Acid; Aspirin; Collagen; Coronary Artery Disease; Female; Guidelines as Topic; Hu | 2009 |
Another look at the results of the JUPITER trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Mass Index; C-Reactive Prot | 2009 |
The prevalence of aspirin resistance in patients with metabolic syndrome.
Topics: Aged; Aspirin; Biomarkers, Pharmacological; Blood Glucose; Blood Pressure; Body Mass Index; Coronary | 2009 |
Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats.
Topics: Animals; Aorta; Aspirin; Blood Pressure; Consciousness; Creatine Kinase; Endothelium, Vascular; Gast | 2010 |
Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Blood Gluco | 2010 |
Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-A(y) mice: structure-activity relationship on zinc-salicylate complexes.
Topics: Adiponectin; Administration, Oral; Animals; Aspirin; Blood Pressure; Coordination Complexes; Diabete | 2011 |
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemor | 2012 |
Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke.
Topics: Age Factors; Aspirin; C-Reactive Protein; Cholesterol; Diabetes Mellitus; Female; Heart Diseases; Hu | 2003 |
The metabolic syndrome--what is it and how should it be managed?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA | 2006 |
Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Comorbidity; Disease Progression; Double-Blind Method | 2006 |
The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Carotid Stenosis; Cross-Sectional Studies; Dose-Respo | 2007 |
Contraceptive patch: new labeling.
Topics: Administration, Cutaneous; Adolescent; Anti-HIV Agents; Aspirin; Colonic Neoplasms; Contraceptive Ag | 2008 |